2021-05-10 12:43:02

10 May 2021 marks the 18th World Lupus Day. Hosted by the Rheumatology and Immunological Rehabilitation Professional Committee of the Chinese Association of Rehabilitation Medicine and the National Clinical Research Center for Skin and Immune Diseases, and supported by GSK, the first batch of "China Standardized Diagnosis and Treatment Center for Systemic Lupus Erythematosus" (hereinafter referred to as "SLE Center") in China was officially launched.

Relying on the National Clinical Research Center for Skin and Immune Diseases, the project is supported by an expert committee composed of many experts in the field of lupus headed by Professor Zeng Xiaofeng, Director of the National Clinical Research Center for Skin and Immune Diseases, Director of the Department of Rheumatology and Immunology of Peking Union Medical College Hospital. It is expected that 42 SLE standardized diagnosis and treatment centers will be completed in 24 provinces, municipalities and autonomous regions this year, covering Beijing, Shanghai, Guangdong, Jiangsu, Zhejiang, Shandong, Chongqing, Hubei, Henan, Liaoning, Xinjiang Uygur Autonomous Region and other regions.

"The standard diagnosis and treatment level of SLE in China needs to be improved. First of all, the number of rheumatology and immunology specialists is insufficient, until now many tertiary hospitals do not have rheumatology and immunology specialists, and many patients will choose to visit different clinics according to clinical symptoms, resulting in the widespread missed diagnosis and misdiagnosis of patients in the early stage of lupus; Secondly, the concept of standard treatment proposed by grassroots doctors in the "2020 China Systematic Lupus Erythematosus Diagnosis and Treatment Guide" is vague, and the management of patient prognosis is not strong, which is not conducive to the overall diagnosis and treatment and rehabilitation of the disease, which brings certain challenges to SLE early screening and early diagnosis, long-term standardized treatment and standard treatment. Professor Zeng Xiaofeng, director of the National Clinical Research Center for Skin and Immune Diseases, director of the Department of Rheumatology and Immunology of Peking Union Medical College Hospital, said.